Adva Biotechnology and Autolomous have announced a collaboration to co-lead the Digital Pioneer Program, an initiative aimed at digitising, decentralising, and scaling autologous cell therapy manufacturing.

The program combines Adva’s automated closed-system manufacturing platform with Autolomous’ digital orchestration and manufacturing management technologies. The integrated model is designed to deliver right-first-time production processes with full data traceability and regulatory compliance, helping to reduce time-to-patient for advanced therapies.

“Through the Digital Pioneer Program, we are inviting cell therapy developers to experience the real-world benefits of a unified, intelligent manufacturing model,” said Ohad Karnieli, founder and chief executive officer of Adva Biotechnology.

“This collaboration is about enabling a new standard—one where automation, digital traceability, and scalability are built into the therapeutic lifecycle from day one.”

“Our mission is to provide a digital-first infrastructure that removes barriers between innovation and the patient,” added Alexander Seyf, co-founder and chief executive officer of Autolomous. “This program offers a foundation to help build the future of personalised medicine.”

The Digital Pioneer Program is now open to cell therapy developers seeking to evaluate and adopt next-generation manufacturing technologies.